A Dominant-negative F-box Deleted Mutant of E3 Ubiquitin Ligase, β-TrCP1/FWD1, Markedly Reduces Myeloma Cell Growth and Survival in Mice

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 May 27

PMID 26009993

Citations 8

Authors

Ramaswamy Sharma

Paul J Williams

Anjana Gupta

Brandon McCluskey

Shylesh Bhaskaran

Steve Munoz

Babatunde O Oyajobi

Affiliations

Soon will be listed here.

Abstract

Treatment of multiple myeloma with bortezomib can result in severe adverse effects, necessitating the development of targeted inhibitors of the proteasome. We show that stable expression of a dominant-negative F-box deleted (âF) mutant of the E3 ubiquitin ligase, SCFβ-TrCP/FWD1, in murine 5TGM1 myeloma cells dramatically attenuated their skeletal engraftment and survival when inoculated into immunocompetent C57BL/KaLwRij mice. Similar results were obtained in immunodeficient bg-nu-xid mice, suggesting that the observed effects were independent of host recipient immune status. Bone marrow stroma offered no protection for 5TGM1-âF cells in cocultures treated with tumor necrosis factor (TNF), indicating a cell-autonomous anti-myeloma effect. Levels of p100, IκBα, Mcl-1, ATF4, total and cleaved caspase-3, and phospho-β-catenin were elevated in 5TGM1-âF cells whereas cIAP was down-regulated. TNF also activated caspase-3 and downregulated Bcl-2, correlating with the enhanced susceptibility of 5TGM1-âF cells to apoptosis. Treatment of 5TGM1 tumor-bearing mice with a β-TrCP1/FWD1 inhibitor, pyrrolidine dithiocarbamate (PDTC), significantly reduced tumor burden in bone. PDTC also increased levels of cleaved Mcl-1 and caspase-3 in U266 human myeloma cells, correlating with our murine data and validating the development of specific β-TrCP inhibitors as an alternative therapy to nonspecific proteasome inhibitors for myeloma patients.

Citing Articles

Beta-Transducin Repeats-Containing Proteins as an Anticancer Target.

Kim D, Yi Y, Seong Y Cancers (Basel). 2023; 15(17).

PMID: 37686524 PMC: 10487276. DOI: 10.3390/cancers15174248.

Research progress of E3 ubiquitin ligase regulating biological behavior of human placental trophoblast cells.

Feng J, Yin H, Baturuhu , Dai Y, Dai F, Xu J Front Endocrinol (Lausanne). 2023; 14:1124041.

PMID: 37168980 PMC: 10165996. DOI: 10.3389/fendo.2023.1124041.

Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway.

Belachew A, Wu X, Callender R, Waller R, Orlowski R, Vachon C Cancer Epidemiol. 2021; 73:101972.

PMID: 34216957 PMC: 8351401. DOI: 10.1016/j.canep.2021.101972.

Regulation of Normal and Malignant Hematopoiesis by FBOX Ubiquitin E3 Ligases.

Willow Hynes-Smith R, Wittorf K, Buckley S Trends Immunol. 2020; 41(12):1128-1140.

PMID: 33160841 PMC: 7704775. DOI: 10.1016/j.it.2020.10.003.

β-TrCP1 promotes cell proliferation via TNF-dependent NF-κB activation in diffuse large B cell lymphoma.

Cai N, Chen Z, Huang Y, Shao S, Yu H, Wang Y Cancer Biol Ther. 2019; 21(3):241-247.

PMID: 31731887 PMC: 7012105. DOI: 10.1080/15384047.2019.1683332.

References

Basak S, Kim H, Kearns J, Tergaonkar V, ODea E, Werner S . A fourth IkappaB protein within the NF-kappaB signaling module. Cell. 2007; 128(2):369-81. PMC: 1831796. DOI: 10.1016/j.cell.2006.12.033. View

Kanarek N, Ben-Neriah Y . Regulation of NF-κB by ubiquitination and degradation of the IκBs. Immunol Rev. 2012; 246(1):77-94. DOI: 10.1111/j.1600-065X.2012.01098.x. View

Kouroukis T, Baldassarre F, Haynes A, Imrie K, Reece D, Cheung M . Bortezomib in multiple myeloma: systematic review and clinical considerations. Curr Oncol. 2014; 21(4):e573-603. PMC: 4117625. DOI: 10.3747/co.21.1798. View

Dallas S, Garrett I, Oyajobi B, Dallas M, Boyce B, Bauss F . Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood. 1999; 93(5):1697-706. View

Borset M, Waage A, Brekke O, Helseth E . TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur J Haematol. 1994; 53(1):31-7. DOI: 10.1111/j.1600-0609.1994.tb00176.x. View

Barkett M, Gilmore T . Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene. 1999; 18(49):6910-24. DOI: 10.1038/sj.onc.1203238. View

Suzuki Y, Nakabayashi Y, Takahashi R . Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci U S A. 2001; 98(15):8662-7. PMC: 37492. DOI: 10.1073/pnas.161506698. View

Mitsiades C, Mitsiades N, Richardson P, Munshi N, Anderson K . Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem. 2007; 101(4):950-68. DOI: 10.1002/jcb.21213. View

Oyajobi B, Franchin G, Williams P, Pulkrabek D, Gupta A, Munoz S . Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood. 2003; 102(1):311-9. DOI: 10.1182/blood-2002-12-3905. View

10.

Keats J, Fonseca R, Chesi M, Schop R, Baker A, Chng W . Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007; 12(2):131-44. PMC: 2083698. DOI: 10.1016/j.ccr.2007.07.003. View

11.

Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville M . NF- kappa B2/p100 induces Bcl-2 expression. Leukemia. 2003; 17(7):1349-56. DOI: 10.1038/sj.leu.2402982. View

12.

Chen L, Smith L, Wang Z, Smith J . Preservation of caspase-3 subunits from degradation contributes to apoptosis evoked by lactacystin: any single lysine or lysine pair of the small subunit is sufficient for ubiquitination. Mol Pharmacol. 2003; 64(2):334-45. DOI: 10.1124/mol.64.2.334. View

13.

Kojima S, Hyakutake A, Koshikawa N, Nakagawara A, Takenaga K . MCL-1V, a novel mouse antiapoptotic MCL-1 variant, generated by RNA splicing at a non-canonical splicing pair. Biochem Biophys Res Commun. 2009; 391(1):492-7. DOI: 10.1016/j.bbrc.2009.11.086. View

14.

Shirane M, Hatakeyama S, Hattori K, Nakayama K . Common pathway for the ubiquitination of IkappaBalpha, IkappaBbeta, and IkappaBepsilon mediated by the F-box protein FWD1. J Biol Chem. 1999; 274(40):28169-74. DOI: 10.1074/jbc.274.40.28169. View

15.

Winston J, Koepp D, Zhu C, Elledge S, Harper J . A family of mammalian F-box proteins. Curr Biol. 1999; 9(20):1180-2. DOI: 10.1016/S0960-9822(00)80021-4. View

16.

Porn-Ares M, Saido T, Andersson T, Ares M . Oxidized low-density lipoprotein induces calpain-dependent cell death and ubiquitination of caspase 3 in HMEC-1 endothelial cells. Biochem J. 2003; 374(Pt 2):403-11. PMC: 1223604. DOI: 10.1042/BJ20021955. View

17.

Ding Q, He X, Hsu J, Xia W, Chen C, Li L . Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol. 2007; 27(11):4006-17. PMC: 1900029. DOI: 10.1128/MCB.00620-06. View

18.

Frescas D, Pagano M . Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer. 2008; 8(6):438-49. PMC: 2711846. DOI: 10.1038/nrc2396. View

19.

Liang C, Zhang M, Sun S . beta-TrCP binding and processing of NF-kappaB2/p100 involve its phosphorylation at serines 866 and 870. Cell Signal. 2005; 18(8):1309-17. DOI: 10.1016/j.cellsig.2005.10.011. View

20.

Hatakeyama S, Kitagawa M, Shirane M, Matsumoto M, Hattori K, Higashi H . Ubiquitin-dependent degradation of IkappaBalpha is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc Natl Acad Sci U S A. 1999; 96(7):3859-63. PMC: 22385. DOI: 10.1073/pnas.96.7.3859. View